羟苯磺酸钙联合前列地尔介导血清抵抗素、脂联素及IGF-1水平治疗糖尿病肾病的疗效分析

目的探讨前列地尔联合羟苯磺酸钙介导血清抵抗素、脂联素及IGF-1水平治疗糖尿病肾病的临床疗效.方法：收集糖尿病肾病患者共109例,随机分为试验组55例和对照组54例,给予常规治疗和密切护理,试验组患者给予前列地尔联合羟苯磺酸钙介导血清抵抗素、脂联素及胰岛素样生长因子（IGF-1）水平治疗糖尿病肾病,对照组仅给予羟苯磺酸钙介导血清抵抗素、脂联素及IGF-1水平治疗,两组患者均治疗12周,比较其疗效差异.结果：治疗前两组患者血清抵抗素、脂联素及IGF-1水平均相近,差异无统计学意义;治疗后两组患者各血清指标均有不同程度下降,但试验组降幅大于对照组,且试验组治疗有效率高于对照组,上述差异均有统计学意义（P〈0.05）.结论：前列地尔联合羟苯磺酸钙介导血清抵抗素、脂联素及IGF-1水平治疗糖尿病肾病具有良好的治疗效果,并显著降低血清抵抗素、脂联素及IGF-1水平.

ObjectiveTo investigate the curative effect of the treatment of diabetic nephropathy by alprostadil combined with calcium dobesilate mediating the levels of serum resistin, diponectin and IGF-1.Methods：Collecting a total of 109 patients who were clinical diagnosed with diabetic nephropathy from January 2013 to May 2014.55 patients were randomly divided into test group and 54 in control group.Besides providing routine therapy and close nursing,the patients in test group were given the treatment of diabetic nephropathy by alprostadil combined with calcium dobesilate mediating the levels of serum resistin, diponectin and IGF-1.While the other 54 patients in control group were merely given the therapy of calcium dobesilate mediating the levels of serum resistin, diponectin and IGF-1.Two groups of patients were treated for 12 weeks and comparing the curative effect differences.Results：The levels of serum resistin, diponectin and IGF-1 were similar in two groups of patients before treatment, which has no statistically significant difference compared by test.After treatment,the serum indexes of the patients had different degree of decline in two groups.The experimental group fell more than the control group and with a better curative effect.By the relevant statistical comparison, the above-mentioned difference had statistical significance （P〈0.05）. Conclusion： Alprostadil in combination with calcium dobesilate mediating the levels of serum resistin, diponectin and IGF-1 has a good treatment effect in therapy of diabetes nephropathy,and significantly reduces the levels of serum resistin ,adiponectin and IGF-1 .